Multicenter phase II trial of nintedanib plus docetaxel in second-line treatment in advanced non-squamous non-small cell lung cancer patients refractory to first-line platin-based chemotherapy (REFRACT GFPC 02-15 study)

The management of patients with non-small cell lung cancer (NSCLC) has considerably changed with the discovery of oncogenic driver mutations (e.g., EGFR, ALK, BRAF, ROS 1), which are potential targets for therapy [1]. Another major breakthrough was the advent of PD-1/PD-L1 immunotherapy allowing patients with PD-L1>50% to be treated with pembrolizumab monotherapy and more recently, regardless of the level of PDL1, to be treated with a combination of pembrolizumab and chemotherapy [2,3]. However, most of these patients with advanced NSCLC receive platin-based chemotherapy associated or not to pembrolizumab as first-line treatment [2,3].

Source: Lung Cancer - September 20, 2021 Category: Cancer & Oncology Authors: Jean-Bernard Auliac, Isabelle Monnet, Acya Bizieux, Laurent Greillier, Margaux Geier, Lionel Falchero, Gwenaelle Le Garff, R égine Lamy, Florian Guisier, Charles Ricordel, Christos Chouaid, Alain Vergnenegre Source Type: research